B Pestalozzi
Choice of first line systemic treatment in pancreatic cancer among national experts
Glatzer M, Pless M, Pederiva S, Pestalozzi B, Berger M, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora P. Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology 2020; 20:686-690.
31.03.2020Choice of first line systemic treatment in pancreatic cancer among national experts
31.03.2020Pancreatology 2020; 20:686-690
Glatzer Markus, Pless M, Pederiva S, Pestalozzi B, Berger M D, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora Paul Martin
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
19.12.2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
19.12.2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
04.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
04.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
13.09.2010Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
13.09.2010Ann Oncol 2010; 22:567-74
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller T, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92.
01.07.2008Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
01.07.2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller Thomas, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Leyvraz S, Pestalozzi B, Dietrich D, Cerny T, Wernli M, Sessa C, Fey M, Christinat A, Honegger H, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer 2006; 95:1342-7.
20.11.2006Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
20.11.2006British journal of cancer 2006; 95:1342-7
Leyvraz S, Pestalozzi B, Dietrich D, Cerny Thomas, Wernli M, Sessa C, Fey M F, Christinat A, Honegger H P, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK)